Nasdaq

Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...
Ophthalmology Times

Evaluating Safety and Clinical Confidence between Aflibercept 8 mg and 2 mg in Retinal Vascular Diseases

Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and ...
Nasdaq

Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review

TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
FiercePharma

EYLEA® (aflibercept) Injection Receives FDA Approval for Macular Edema Following Retinal Vein Occlusion (RVO)

EYLEA Now Approved for Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Macular Edema following RVO TARRYTOWN, N.Y., Oct. 6, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals ...
Healthline

Does Medicare Cover Eylea?

Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...
FiercePharma

EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema

TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA® (aflibercept) ...
Healio

FDA approves Enzeevu, aflibercept biosimilar for neovascular AMD

Please provide your email address to receive an email when new articles are posted on . The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of ...
Healio

At 2 years, aflibercept injections did not impact CNV conversion rates

CHICAGO — The 24-month results of the PRO-CON study did not demonstrate a benefit of intravitreal aflibercept injection as prophylaxis against the conversion to neovascular age-related macular ...
WPRI 12

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
MedPage Today

Early Enthusiasm for Cancer Drug Reformulated for Ophthalmic Use

Both the axitinib (Inlyta)-containing OTX-TKI implant and bimonthly aflibercept (Eylea) produced a 1- to 2-letter improvement in best-corrected visual acuity (BCVA) at 52 weeks, while mean central ...
Seeking Alpha

EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA

TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA ® (aflibercept) Injection ...